Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 23 citing articles:

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 45
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 397-397
Open Access | Times Cited: 20
Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 3
Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data
Hisayuki Katsuyama, Mariko Hakoshima, Emika Kaji, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 5
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Motij Kumar Dalai, Sanjay Chandnani
Hepatology International (2025)
Closed Access
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Non-Alcoholic Fatty Liver Disease
В. Т. Ивашкин, О. М. Драпкина, M. V. Maevskaya, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2025) Vol. 35, Iss. 1, pp. 94-152
Open Access
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Manuela Vitulo, Elisa Gnodi, Giulia Rosini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12748-12748
Open Access | Times Cited: 11
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study
J. Yeh, Philip N. Newsome
Hepatology (2024) Vol. 79, Iss. 6, pp. 1255-1257
Open Access | Times Cited: 3
Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism
Xiaoxi Feng, Rutong Zhang, Zhenye Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 3
Cav3.2 deletion attenuates nonalcoholic fatty liver disease in mice
Xue Li, Chengyun Hu, Shanshan Luo, et al.
Gene (2024) Vol. 929, pp. 148812-148812
Open Access | Times Cited: 2
Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1
Yue-Hua Yin, Li-Xuan Sang, Bing Chang
World Journal of Gastroenterology (2023) Vol. 29, Iss. 48, pp. 6235-6238
Open Access | Times Cited: 4
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Meng‐Tzu Weng, Po‐Jen Yang, Pan-Fu Liu, et al.
Hepatology International (2024)
Closed Access | Times Cited: 1
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update
André Scheen
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 8, pp. 543-553
Closed Access | Times Cited: 3
Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
Marcin Hachuła, Michał Kosowski, Marcin Basiak, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1190-1190
Open Access | Times Cited: 2
Obesity management for the hepatologist—What to do, how to do it and why?
Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, et al.
Hepatology (2023)
Closed Access | Times Cited: 2
Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Basile Njei, Yazan A. Al‐Ajlouni, Samira Yaya Lemos, et al.
Authorea (Authorea) (2024)
Open Access
Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension
Yeting Chang, Yu Qin
Iranian Journal of Public Health (2024)
Open Access
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Basile Njei, Yazan A. Al‐Ajlouni, Samira Yaya Lemos, et al.
Cureus (2024)
Open Access
Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis
Carlos U. Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, et al.
Diabetology International (2024) Vol. 16, Iss. 1, pp. 65-77
Closed Access
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 1


Diabetes Obesity Metabolic Syndrome (2023), Iss. 5
Open Access
Page 1

Scroll to top